Nasdaq Clbs News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nasdaq clbs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nasdaq Clbs Today - Breaking & Trending Today
Equities research analysts expect Caladrius Biosciences, Inc. (NASDAQ:CLBS – Get Rating) to report ($0.10) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Caladrius Biosciences’ earnings. The highest EPS estimate is ($0.06) and the lowest is ($0.12). Caladrius Biosciences also reported earnings per share of ($0.10) […] ....
Caladrius Biosciences, Inc. (NASDAQ:CLBS – Get Rating) was the target of a significant drop in short interest during the month of May. As of May 15th, there was short interest totalling 541,400 shares, a drop of 43.1% from the April 30th total of 952,200 shares. Currently, 0.9% of the company’s shares are sold short. Based […] ....
Caladrius Biosciences (NASDAQ:CLBS – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Tuesday, Zacks.com reports. The firm presently has a $0.50 price objective on the biotechnology company’s stock. Zacks Investment Research‘s target price indicates a potential upside of 8.65% from the stock’s […] ....
Caladrius Biosciences (NASDAQ:CLBS – Get Rating) issued its earnings results on Thursday. The biotechnology company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03, MarketWatch Earnings reports. During the same period in the prior year, the company earned ($0.19) earnings per share. Shares of NASDAQ CLBS traded down […] ....
StockNews.com assumed coverage on shares of Caladrius Biosciences (NASDAQ:CLBS – Get Rating) in a report released on Tuesday. The brokerage issued a sell rating on the biotechnology company’s stock. Separately, HC Wainwright cut their price target on Caladrius Biosciences from $8.00 to $6.00 and set a buy rating on the stock in a research note […] ....